Orencia now available in subcutaneous formulationRheumatoid arthritis drug now available in two formats. Lupus patients often fail to get Pap testsScreening falls short despite higher risk for cervical dysplasia Brain ‘awry’ in fibromyalgia Scans help explain why these patients don’t respond well to opioids Biologics linked with reduced mortality in rheumatoid arthritis Those on biologics also spent fewer days in hospital Proximity to uranium plant linked with lupus Studies suggest estrogen-like effects could help explain the finding Health Canada approves Cymbalta for the management of osteoarthritis knee pain Test reveals arthritis risk Clinical Notes: Canadian RA guidelines address drug safety concerns New recommendations focus on the safety of traditional and biologic disease-modifying antirheumatic drugs Research Highlights: Cephalosporin use in penicillin allergy Review evaluates literature pertaining to cross-reactivity between penicillins and cephalosporins. New Canadian guidelines for fibromyalgia management Document incorporates new evidence concerning pathogenesis, more diverse treatment strategies. Cymbalta now indicated for managing chronic OA knee pain This is the sixth Health Canada-approved indication for Cymbalta. Canadian rheumatoid arthritis guidelines address specific drug safety concerns Document addresses several specific safety concerns related to the use of traditional and biologic DMARDs in patients. First Previous 13 14 15 16 17 Next Last
